AU2020281332B2 - Dna-dependent protein kinase inhibitor - Google Patents

Dna-dependent protein kinase inhibitor

Info

Publication number
AU2020281332B2
AU2020281332B2 AU2020281332A AU2020281332A AU2020281332B2 AU 2020281332 B2 AU2020281332 B2 AU 2020281332B2 AU 2020281332 A AU2020281332 A AU 2020281332A AU 2020281332 A AU2020281332 A AU 2020281332A AU 2020281332 B2 AU2020281332 B2 AU 2020281332B2
Authority
AU
Australia
Prior art keywords
methyl
pyrazolo
pyrimidin
amine
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020281332A
Other languages
English (en)
Other versions
AU2020281332A8 (en
AU2020281332A1 (en
Inventor
Changhe Qi
Honchung TSUI
Zhenfan YANG
Qingbei Zeng
Xiaolin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dizal Jiangsu Pharmaceutical Co Ltd
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of AU2020281332A1 publication Critical patent/AU2020281332A1/en
Publication of AU2020281332A8 publication Critical patent/AU2020281332A8/en
Application granted granted Critical
Publication of AU2020281332B2 publication Critical patent/AU2020281332B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020281332A 2019-05-27 2020-05-26 Dna-dependent protein kinase inhibitor Active AU2020281332B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/088573 2019-05-27
CN2019088573 2019-05-27
PCT/CN2020/092351 WO2020238900A1 (en) 2019-05-27 2020-05-26 Dna-dependent protein kinase inhibitor

Publications (3)

Publication Number Publication Date
AU2020281332A1 AU2020281332A1 (en) 2021-11-04
AU2020281332A8 AU2020281332A8 (en) 2021-11-18
AU2020281332B2 true AU2020281332B2 (en) 2026-04-02

Family

ID=73551904

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020281332A Active AU2020281332B2 (en) 2019-05-27 2020-05-26 Dna-dependent protein kinase inhibitor

Country Status (12)

Country Link
US (1) US12630565B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976624A4 (cg-RX-API-DMAC7.html)
JP (1) JP7696834B2 (cg-RX-API-DMAC7.html)
KR (1) KR102961371B1 (cg-RX-API-DMAC7.html)
CN (1) CN113924305A (cg-RX-API-DMAC7.html)
AR (1) AR119018A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020281332B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023824A8 (cg-RX-API-DMAC7.html)
CA (1) CA3137598A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014455A (cg-RX-API-DMAC7.html)
TW (1) TWI899080B (cg-RX-API-DMAC7.html)
WO (1) WO2020238900A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021213460A1 (zh) * 2020-04-23 2021-10-28 山东轩竹医药科技有限公司 三并环类激酶抑制剂
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
WO2022148354A1 (zh) * 2021-01-05 2022-07-14 山东轩竹医药科技有限公司 多环类激酶抑制剂
WO2022177302A1 (ko) * 2021-02-17 2022-08-25 보령제약 주식회사 Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도
CN116023394B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
CN116023393B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CA3245866A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
CN117003754B (zh) * 2022-04-28 2025-07-25 腾讯科技(深圳)有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
CN115322209B (zh) * 2022-07-19 2023-06-20 湖北理工学院 作为dna-pk抑制剂的三并环化合物
CN116239610B (zh) * 2023-02-23 2024-01-16 遵义医科大学珠海校区 一种嘧啶衍生物及其制备方法与在制备抗肿瘤药物中的应用
EP4720069A4 (en) * 2023-07-21 2026-07-22 Wei Zhong Substituted 2-AMINO-9-(3,3-DIFLOOROPIPERIDIN-4-YL)-7,9-DIHYDRO-8H-PURIN-8-ONE COMPOUNDS AND THEIR USE IN CANCER TREATMENT
WO2025179188A1 (en) * 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2006074984A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
WO2006074985A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2007140222A2 (en) * 2006-05-26 2007-12-06 Novartis Ag Pyrrolopyrimidine compounds and their uses
WO2011156698A2 (en) * 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012022681A2 (en) * 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
CN102666545A (zh) * 2009-10-20 2012-09-12 塞尔卓姆有限公司 作为jak抑制剂的杂环吡唑并嘧啶类似物
CN103180322A (zh) * 2010-04-30 2013-06-26 塞尔佐姆有限公司 作为jak抑制剂的吡唑化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070104936A (ko) 2005-02-16 2007-10-29 아스트라제네카 아베 화합물
JP2006241089A (ja) * 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
WO2011106168A1 (en) * 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
US20130035336A1 (en) * 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
KR20140063700A (ko) 2011-09-20 2014-05-27 셀좀 리미티드 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
RS62649B1 (sr) * 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
WO2015115673A1 (en) * 2014-01-31 2015-08-06 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
DK3558997T3 (da) * 2016-12-20 2021-04-19 Astrazeneca Ab Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
JP7230053B2 (ja) 2017-12-05 2023-02-28 オスコテック インコーポレイテッド Lrrk2阻害剤としてのピロロ(ピラゾロ)ピリミジン誘導体
TWI820146B (zh) 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
CN110885331B (zh) 2018-09-11 2021-07-09 中国药科大学 一种6-氨基-1H-吡唑并[3,4-d]嘧啶类JAK激酶抑制剂的制备与应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2006074984A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
WO2006074985A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2007140222A2 (en) * 2006-05-26 2007-12-06 Novartis Ag Pyrrolopyrimidine compounds and their uses
CN102666545A (zh) * 2009-10-20 2012-09-12 塞尔卓姆有限公司 作为jak抑制剂的杂环吡唑并嘧啶类似物
CN103180322A (zh) * 2010-04-30 2013-06-26 塞尔佐姆有限公司 作为jak抑制剂的吡唑化合物
WO2011156698A2 (en) * 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012022681A2 (en) * 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors

Also Published As

Publication number Publication date
AU2020281332A8 (en) 2021-11-18
JP2022534261A (ja) 2022-07-28
BR112021023824A8 (pt) 2023-02-28
AU2020281332A1 (en) 2021-11-04
US12630565B2 (en) 2026-05-19
EP3976624A4 (en) 2023-06-14
TW202110849A (zh) 2021-03-16
US20220242884A1 (en) 2022-08-04
BR112021023824A2 (pt) 2022-01-04
KR20220027062A (ko) 2022-03-07
CN113924305A (zh) 2022-01-11
CA3137598A1 (en) 2020-12-03
JP7696834B2 (ja) 2025-06-23
EP3976624A1 (en) 2022-04-06
TWI899080B (zh) 2025-10-01
KR102961371B1 (ko) 2026-05-06
WO2020238900A1 (en) 2020-12-03
AR119018A1 (es) 2021-11-17
MX2021014455A (es) 2022-01-06

Similar Documents

Publication Publication Date Title
US12630565B2 (en) DNA-dependent protein kinase inhibitor
US12472181B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2018385664B2 (en) Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
US10858365B2 (en) Triazolo-pyrimidine compounds and uses thereof
EP3237423B1 (en) Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors
US10450296B2 (en) Heterocyclic compounds useful as Pim kinase inhibitors
JP6437452B2 (ja) Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
US20250059205A1 (en) Heterocyclic Compounds and Methods of Use
US20190209537A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
KR20200096571A (ko) 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물
AU2014228175A1 (en) Tricyclic heterocycles as BET protein inhibitors
EP4086259A1 (en) Heterocyclic compounds as pi3k-gamma inhibitors
RS56731B1 (sr) Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze
JP2026501699A (ja) Cdk2阻害剤
RU2835434C2 (ru) Ингибитор ДНК-зависимой протеинкиназы
WO2016001077A1 (en) Compounds inhibiting the enzyme monopolar spindle 1 kinase,pharmaceutical compositions and uses thereof
HK40060710A (en) Dna-dependent protein kinase inhibitor
RU2785126C2 (ru) Новые соединения и их фармацевтические композиции для лечения воспалительных заболеваний
US20250235456A1 (en) Methods of use for aza-quinazoline compounds
HK1237340A1 (en) Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors
HK1237340B (en) Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 35 , NO 44 , PAGE(S) 8605 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.; ADVENCHEN PHARMACEUTICALS, LLC, APPLICATION NO. 2020281332, UNDER INID (71) REMOVE CO-APPLICANT ADVENCHEN PHARMACEUTICALS, LLC

FGA Letters patent sealed or granted (standard patent)